Daniel Sandi
Overview
Explore the profile of Daniel Sandi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sandi D, Kokas Z, Kincses Z, Fuvesi J, Fricska-Nagy Z, Voros E, et al.
Heliyon
. 2024 Nov;
10(20):e39536.
PMID: 39502229
Introduction: Natalizumab (NAT), a highly effective disease modifying therapy (DMT) in relapsing-remitting multiple sclerosis (RRMS), was approved for clinical use in Hungary on February 1, 2010. In this study we...
2.
Nyari A, Kokas Z, Szamosi S, Fricska-Nagy Z, Kincses Z, Fuvesi J, et al.
Neurol Sci
. 2024 Aug;
46(1):325-334.
PMID: 39174771
Background: There is scarce information in Middle-Eastern Europe regarding the prevalence of anxiety in patients with multiple sclerosis (pwMS) and its association with different clinical-demographic factors. Objective: We aimed to...
3.
Ronaszeki B, Sandi D, Onodi A, Szabo N, Dezsi L, Tajti J, et al.
Ideggyogy Sz
. 2024 Jun;
77(5-6):212-216.
PMID: 38829245
Background - POEMS syndrome is a potentially well manageable disease with an ascendant therapeutic arsenal nowadays. The early recognition of the syndrome is key to prevent serious multiorgan damage, and...
4.
Nyari A, Kokas Z, Szamosi S, Fricska-Nagy Z, Fuvesi J, Kincses Z, et al.
Neurol Sci
. 2024 Jan;
45(7):3369-3378.
PMID: 38280085
Background: Cognitive impairment (CI) is a frequent symptom of multiple sclerosis (MS) and has a great impact on the patients' quality of life, so screening is essential. The brief international...
5.
Kokas Z, Jardanhazy A, Sandi D, Biernacki T, Fricska-Nagy Z, Fuvesi J, et al.
Mult Scler Relat Disord
. 2022 Nov;
69:104406.
PMID: 36413917
Background: In 2018 multiple sclerosis (MS) care unit (MSCU) recommendations were defined. Nevertheless, the information on MS care, and whether MS centres fulfil the international recommendation is limited. Thus our...
6.
Sandi D, Kokas Z, Biernacki T, Bencsik K, Klivenyi P, Vecsei L
Int J Mol Sci
. 2022 May;
23(9).
PMID: 35563559
Multiple sclerosis (MS) is the inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS) that affects approximately 2.8 million people worldwide. In the last decade, a new era...
7.
Biernacki T, Sandi D, Fuvesi J, Fricska-Nagy Z, Kincses T, Acs P, et al.
PLoS One
. 2022 Apr;
17(4):e0267346.
PMID: 35452476
Background: Fingolimod was approved and reimbursed by the healthcare provider in Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in 2012. The present study aimed to assess...
8.
Biernacki T, Kokas Z, Sandi D, Fuvesi J, Fricska-Nagy Z, Farago P, et al.
Int J Mol Sci
. 2022 Mar;
23(6).
PMID: 35328802
Introduction: Multiple Sclerosis (MS) is the most common immune-mediated chronic neurodegenerative disease of the central nervous system (CNS) affecting young people. This is due to the permanent disability, cognitive impairment,...
9.
Kokas Z, Sandi D, Fricska-Nagy Z, Fuvesi J, Biernacki T, Koves A, et al.
PLoS One
. 2022 Mar;
17(3):e0264328.
PMID: 35239686
A Patients: Because of the past 3 decades' extensive research, several disease modifying therapies became available, thus a paradigm change is multiple sclerosis care was necessary. In 2018 a therapeutic...
10.
Farago P, Toth E, Szabo N N, Kocsis K, Kincses B, Bozsik B, et al.
Mult Scler Relat Disord
. 2021 Dec;
57:103442.
PMID: 34896877
Background: Cognitive decline is a prominent symptom of MS. Clear connection between cognitive status and white matter microstructural changes has not been unequivocally observed to date. Objective: To characterise the...